- Home
- MRK
MRK
Merck & Company Inc. (new)
as 11-21-2024 4:00pm EST
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | KENILWORTH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $132.08 | AVG Volume (30 days): | 10.8M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.78 | EPS Growth: | 165.47 |
| 52 Week Low/High: | $94.48 - $134.63 | Next Earning Date: | 10-31-2024 |
| Revenue: | $63,174,000,000 | Revenue Growth: | 6.51% |
| Revenue Growth (this year): | 7.52% | Revenue Growth (next year): | 4.77% |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Business Wire
10 hours ago
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
Pharma Voice
15 hours ago
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
ACCESSWIRE
a day ago
Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
Insider Monkey
a day ago
Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
MT Newswires
a day ago
CFRA Upgrades Merck to Buy
Benzinga
2 days ago
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Business Wire
2 days ago
Merck Announces First-Quarter 2025 Dividend
BioPharma Dive
2 days ago
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.